Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPIs and cardiovascular risk
NCT02022280Phase 1Completed
- Sponsor
- Stanford University
- Start
- Mar 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lansoprazole in endothelial dysfunction (2 arms), sponsored by Stanford University. Primary endpoint: Change in reactive hyperemia index at 12 weeks. Started Mar 2013; status: completed.
02
Drugs
lansoprazole
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT02022280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022280.